Augumenting Anti- Cancer Therapy Using the Immune System and Cytokines

Lung cancer is one of the most common cancer types, yet many of the most ground-breaking cancer immunology therapies are ineffective. Determining proper cytokine dosages to stimulate proliferation is vital to furthering efficacy of lung cancer immunology research. Refining the efficacy of T Cell proliferation advances cancer immunotherapy for melanoma patients. Based on prior research, IL-2 and IL-15 are similar stimulants that activate T cells. They prove to be equally effective, except IL-2 stimulated cells are bigger and show more growth. In lab, mouse spleen cells underwent a CD3 stimulation to observe the difference between IL-2 stimulated cells and IL-15 stimulated cell and to determine which interleukin concentration is most effective and least toxic to cells IL-15 stimulated cells and IL-2 stimulated cells both showed similar results. They both proliferated at about the same rate at about the same dosages. It was concluded, IL-2 induce proliferation in activated T Cells, but do not induce proliferation in naïve T Cells. IL-2 and IL-15 both prove to be able to best induce proliferation of T cells at similar dosages